Showing results (121-130 of 254) with videos related to

Sort By:
Pageof 26
Clinical & Translational Immunology|January 13, 2021
Successful identification of predictive profiles for infection utilising systems-level immune analysis: a pilot study in patients with relapsed and refractory multiple myelomaMarcel Doerflinger, Alexandra L Garnham, Saskia Freytag, et al.
Aesthetic Surgery Journal|November 19, 2019
Breast Implant-Associated Anaplastic Large Cell Lymphoma in Australia: A Longitudinal Study of Implant and Other Related Risk FactorsAnna Loch-Wilkinson, Kenneth J Beath, Mark R Magnusson, et al.
Journal of Personalized Medicine|November 26, 2025
Personalized Immunotherapy for T Cell Lymphomas: From Immune Escape to Precision TherapeuticsJoshua M L Casan, Xiao Jing Ong, Carrie van der Weyden, et al.
Cancers|November 13, 2021
Gram-Negative Bacterial Lipopolysaccharide Promotes Tumor Cell Proliferation in Breast Implant-Associated Anaplastic Large-Cell LymphomaMaria Mempin, Honghua Hu, Karen Vickery, et al.
The British Journal of Ophthalmology|August 8, 2008
Risk factors for delayed suprachoroidal haemorrhage following glaucoma surgeryV S E Jeganathan, S Ghosh, J B Ruddle, et al.
Blood|October 28, 2010
The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapyAndy K Hsu, Hang Quach, Tsin Tai, et al.
Oncoimmunology|November 21, 2015
CAR-T cells are serial killersAlexander J Davenport, Misty R Jenkins, David S Ritchie, et al.
British Journal of Haematology|June 25, 2025
Large-cell transformation of mycosis fungoides: Patterns of care and patient outcomesPhilippa Johnstone, Martin Higgins, H Miles Prince, et al.
Leukemia & Lymphoma|March 12, 2010
Phase II study of autologous stem cell transplant using busulfan-melphalan chemotherapy-only conditioning followed by interferon for relapsed poor prognosis follicular non-Hodgkin lymphomaAndrew P Grigg, Janey Stone, Alvin D Milner, et al.
Leukemia & Lymphoma|April 25, 2007
Early therapeutic response assessment by (18)FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: isolated residual positivity involving bone is not usually a predictor of subsequent treatment failureAshley P Ng, Andrew Wirth, John F Seymour, et al.
Pageof 26